Tirzepatide, a first-in-class dual GIP and GLP-1 receptor agonist, showed potent blood sugar lowering and weight loss in early trials, setting the stage for its landmark SURPASS phase 3 program.
Dual GIP + GLP-1 activationTirzepatide is the first 'twincretin' — a single peptide that activates both incretin receptors, producing synergistic effects on insulin, blood sugar, and body weight
What the researchers found
Tirzepatide is a synthetic 39-amino-acid peptide that activates both GIP and GLP-1 receptors simultaneously — a first-in-class 'twincretin.' Early clinical trials (phase 1 and 2) demonstrated potent glucose-lowering and weight loss effects with a side effect profile comparable to existing GLP-1 receptor agonists.
The dual-agonist concept was built on research showing that co-infusion of GIP and GLP-1 together produces synergistic effects — significantly greater insulin response and glucagon suppression than either hormone alone. Tirzepatide is built on the native GIP sequence with modifications that also activate the GLP-1 receptor, representing a new pharmacological approach to type 2 diabetes.
Why it matters
GLP-1 receptor agonists like semaglutide were already transforming diabetes treatment, but tirzepatide's dual-receptor approach takes the concept further. By harnessing both incretin pathways simultaneously, tirzepatide has since shown in the completed SURPASS trials even greater glucose lowering and weight loss than single-target GLP-1 drugs. This review captured the state of knowledge just before those landmark phase 3 results, documenting the scientific rationale that led to one of the most significant diabetes drugs in recent history.
The numbers in context
39 amino acids · dual GIP/GLP-1 agonist · based on native GIP sequence · SURPASS phase 3 program · phase 1-2 data showing potent glucose + weight effects
How the study worked
Narrative review summarizing preclinical data, phase 1, and phase 2 clinical trial results for tirzepatide in type 2 diabetes, along with an overview of the planned SURPASS phase 3 clinical trial program.
Who was studied
Review covering phase 1-2 trial data in adults with type 2 diabetes
What this study cannot tell us
This review was published before the SURPASS phase 3 trial results were available, so it relies on early-phase data only. Long-term efficacy, safety, and cardiovascular outcomes were unknown at the time of publication. The review does not include head-to-head comparisons with GLP-1 agonists from controlled trials.
How to read the evidence
This is rated Moderate because it reviews phase 1 and 2 clinical trial data, which demonstrate proof-of-concept but are not definitive. The phase 3 SURPASS results were not yet available when this review was published.
When this study was published
Published in early 2021, this review preceded the SURPASS phase 3 trial results. Tirzepatide has since been approved by the FDA (2022) and its efficacy confirmed in multiple large trials. The review remains valuable for understanding the scientific rationale behind the drug's development.
The bigger picture
Tirzepatide represented a paradigm shift in metabolic medicine — proving that targeting multiple incretin receptors simultaneously could produce dramatically better outcomes than targeting one alone. This dual-agonist approach has since expanded to triple agonists (like retatrutide) and has reshaped how pharmaceutical companies think about metabolic drug design. The SURPASS trials, previewed in this review, would go on to show unprecedented HbA1c reductions and weight loss, leading to tirzepatide's approval as both Mounjaro (diabetes) and Zepbound (weight loss).
Questions still open
- Would the SURPASS phase 3 trials confirm the potent effects seen in early-phase studies, and how would tirzepatide compare head-to-head with semaglutide?
- Does GIP receptor activation contribute meaningfully to weight loss, or is the GLP-1 component doing most of the work?
- What are the long-term cardiovascular effects of dual incretin receptor activation?
Common questions
What makes tirzepatide different from semaglutide and other GLP-1 drugs?
Why was GIP not previously considered useful for diabetes treatment?
Read the original research
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.
Diabetes therapy : research, treatment and education of diabetes and related disorders, 12(1), 143-157
Citation
Min, Thinzar; Bain, Stephen C. (2021). The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 12(1), 143-157. https://doi.org/10.1007/s13300-020-00981-0